On December 10, Mega Healthcare (301363) announced via the Hudongyi platform that it has successfully integrated into the core supply chain for invasive brain-computer interface products. The company is now deeply collaborating with downstream clients, guiding them through the entire journey from laboratory R&D to mass production and delivery, and has already started to see small but significant sales revenues.

In the realm of brain-computer interfaces, "invasive" typically refers to devices that are implanted directly into the brain tissue. This is in contrast to "non-invasive" devices, which interact with the brain through external sensors, and "semi-invasive" devices that might be placed on the surface of the brain but not fully implanted. Mega Healthcare's move into this cutting-edge field signifies its commitment to innovation and its ability to adapt to emerging technological trends.

Looking ahead, Mega Healthcare has ambitious plans to extend its reach across the entire spectrum of brain-computer interface products. This includes not only invasive devices but also non-invasive and semi-invasive options, ensuring a comprehensive coverage of this rapidly evolving market.